Profile data is unavailable for this security.
About the company
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2020
- Employees1.37k
- LocationGrail Inc1525 O'brien DriveMENLO PARK 94025United StatesUSA
- Phone+1 (650) 771-9796
- Fax+1 (302) 655-5049
- Websitehttps://www.galleri.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mind Medicine (MindMed) Inc | 0.00 | -97.80m | 519.92m | 57.00 | -- | 2.21 | -- | -- | -1.99 | -1.99 | 0.00 | 3.21 | 0.00 | -- | -- | 0.00 | -42.40 | -- | -49.28 | -- | -- | -- | -- | -- | -- | -- | 0.0849 | -- | -- | -- | -68.55 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -305.81m | 524.68m | 328.00 | -- | 1.79 | -- | -- | -1.41 | -1.41 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -51.36 | -38.99 | -56.78 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Astria Therapeutics Inc | 0.00 | -100.04m | 527.01m | 59.00 | -- | 2.14 | -- | -- | -2.09 | -2.09 | 0.00 | 6.05 | 0.00 | -- | -- | 0.00 | -36.02 | -64.48 | -37.72 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| IGM Biosciences Inc | 2.92m | -219.84m | 527.34m | 198.00 | -- | 6.69 | -- | 180.72 | -3.65 | -3.65 | 0.0484 | 1.33 | 0.0075 | -- | -- | 13,026.79 | -56.45 | -44.66 | -63.54 | -48.20 | -- | -- | -7,534.03 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Organogenesis Holdings Inc | 455.04m | -7.38m | 532.95m | 862.00 | -- | 1.91 | 56.65 | 1.17 | -0.0567 | -0.0567 | 3.43 | 2.10 | 1.00 | 4.09 | 4.78 | 527,886.30 | -1.62 | 5.46 | -1.97 | 6.90 | 75.29 | 74.94 | -1.62 | 4.81 | 2.74 | 6.56 | 0.1875 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 534.49m | 267.00 | -- | -- | -- | 1.41 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Annexon Inc | 0.00 | -117.50m | 546.23m | 84.00 | -- | 1.65 | -- | -- | -1.04 | -1.04 | 0.00 | 3.14 | 0.00 | -- | -- | 0.00 | -40.34 | -44.06 | -43.09 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Humacyte Inc | 0.00 | -152.87m | 547.63m | 183.00 | -- | -- | -- | -- | -1.34 | -1.34 | 0.00 | -0.5317 | 0.00 | -- | -- | 0.00 | -115.74 | -- | -134.05 | -- | -- | -- | -- | -- | -- | -27.44 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Grail Inc | -100.00bn | -100.00bn | 550.38m | 1.37k | -- | 0.2102 | -- | -- | -- | -- | -- | 77.93 | -- | -- | -- | -- | -- | -47.45 | -- | -48.55 | -- | -- | -- | -5,118.86 | -- | -- | -- | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| MBX Biosciences Inc | -100.00bn | -100.00bn | 551.72m | 36.00 | -- | 2.03 | -- | -- | -- | -- | -- | 8.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -95.78m | 555.97m | 58.00 | -- | 0.4148 | -- | -- | -13.15 | -13.15 | 0.00 | 18.37 | 0.00 | -- | -- | 0.00 | -46.34 | -32.54 | -50.90 | -34.09 | -- | -- | -- | -4,308.11 | -- | -- | 0.0711 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Savara Inc | 0.00 | -82.94m | 556.05m | 37.00 | -- | 2.78 | -- | -- | -0.4452 | -0.4452 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -39.41 | -36.86 | -41.56 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1175 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -56.83m | 559.21m | 28.00 | -- | 45.09 | -- | -- | -0.9262 | -0.9262 | 0.00 | 0.1983 | 0.00 | -- | -- | 0.00 | -102.63 | -38.31 | -199.23 | -43.34 | -- | -- | -- | -- | -- | -34.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Tourmaline Bio Inc | 0.00 | -48.85m | 582.60m | 44.00 | -- | 1.81 | -- | -- | -1.68 | -1.68 | 0.00 | 12.52 | 0.00 | -- | -- | 0.00 | -20.37 | -- | -21.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| CRCM LPas of 09 Oct 2024 | 3.64m | 11.74% |
| Sessa Capital IM LPas of 30 Sep 2024 | 3.00m | 9.66% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 2.18m | 7.03% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.45m | 4.67% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 892.91k | 2.88% |
| One Fin Capital Management LPas of 30 Sep 2024 | 650.00k | 2.09% |
| Potrero Capital Research LLCas of 30 Sep 2024 | 506.28k | 1.63% |
| AQR Capital Management LLCas of 30 Sep 2024 | 485.82k | 1.57% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 436.58k | 1.41% |
| abrdn, Inc.as of 30 Sep 2024 | 428.77k | 1.38% |
